publication date: Dec. 12, 2014

Daniel Hayes Elected President of ASCO


Daniel Hayes was elected president of the American Society of Clinical Oncology.

The three-year appointment begins with Hayes becoming president-elect on June 1, 2015. He will serve as president from June 1, 2016, to May 31, 2017, and will serve as immediate past-president for the year after.

Hayes is the clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.

“I’m honored to be elected incoming president of ASCO, which has had such a major influence on my professional career,” says Hayes, the Stuart B. Padnos Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center.

Prior to joining the faculty at the University of Michigan, he held academic appointments at Harvard Medical School and Georgetown University Medical Center.

Hayes has previously served on the ASCO board of directors and has chaired several ASCO guideline committees and its scientific program committee. He has also served as a charter member and co-chair of ASCO’s Tumor Marker Guideline Expert Panel.

Hayes serves as chair of the Breast Cancer Intergroup of North America’s Correlative Sciences Committee, chair of the Southwest Oncology Group’s Breast Cancer Translational Medicine Committee, and is on the Union for International Cancer Control TNM Expert Advisory Panel on Breast Tumours and the Early Breast Cancer Clinical Trials Collaborative Group Executive Committee.

According to ASCO, his term will focus on including new strategies for health care reform; the development of ASCO’s CancerLinQ and other efforts; personalized cancer care; and reducing disparities.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.